Symeres Acquires DGr Pharma to Strengthen Integrated Drug Development Services
核心洞察
Symeres (搜索), a global contract research, development and manufacturing organization, has acquired Netherlands-based DGr Pharma (搜索) to expand its integrated early-stage drug development capabilities.
DGr Pharma (搜索) specializes in pre-clinical and clinical regulatory strategy with expertise in small and large molecules, including antibodies (搜索), ADCs (搜索) and oligonucleotides.
The acquisition enhances Symeres (搜索)' regulatory depth and provides clients with more efficient pathways to IND submission through DGr Pharma (搜索)'s GCP and GLP-compliant services.
Symeres (搜索), a global contract research, development and manufacturing organization (CRDMO), has acquired DGr Pharma (搜索), a drug development-focused consultancy, to expand its integrated early-stage drug development services and accelerate IND-enabling capabilities for biopharma clients. The acquisition is supported by Keensight Capital (搜索), a private equity manager dedicated to pan-European Growth Buyout investments.
Strategic Expansion of Regulatory Capabilities
Founded in 2018 and based in the Netherlands, DGr Pharma (搜索) specializes in pre-clinical and clinical regulatory strategy and consultancy for biotech and pharmaceutical partners working in early drug development. The company's core services include chemical-pharmaceutical, non-clinical and clinical development planning, quality assurance, and regulatory submissions.
DGr Pharma (搜索) brings deep expertise in small and large molecules, including antibodies (搜索), ADCs (搜索) and oligonucleotides. With a reputation for scientific rigor, DGr Pharma adds significant regulatory depth to the Symeres (搜索) portfolio, enabling it to deliver a more integrated solution across the full spectrum of drug discovery and development.
Enhanced Data Quality and Regulatory Readiness
A key component of the acquisition is DGr Pharma (搜索)'s pharmacokinetic data analysis services, which operate under Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) standards. This expertise aligns with Symeres (搜索)' integrated offering, including ADME capabilities. The GLP status enhances data quality and regulatory readiness, providing Symeres' clients with a more efficient and reliable path to IND submission.
Leadership Perspectives on the Acquisition
Guillaume Jetten, CEO of Symeres (搜索), emphasized the strategic value of the acquisition: "This acquisition strengthens our ability to offer truly integrated solutions across the drug discovery and development spectrum. DGr Pharma (搜索)'s expertise enhances our scientific capabilities, allowing us to better support our clients' evolving needs and reinforce Symeres' position as a partner of choice in the global biopharma market."
Kees Groen, Founder and CEO of DGr Pharma (搜索), expressed enthusiasm about joining Symeres (搜索): "This is an exciting new chapter for DGr Pharma. Joining Symeres provides us with the opportunity to grow our reach and expand the value we bring to clients, particularly in early-stage development. We share Symeres' commitment to high-quality science, long-term relationships and entrepreneurial ambition and we look forward to being part of the next phase of growth."
Impact on Drug Development Services
The acquisition positions Symeres (搜索) to offer more comprehensive drug development services by combining DGr Pharma (搜索)'s regulatory expertise with its existing capabilities. This integration is expected to streamline the drug development process for clients, particularly in the critical early stages where regulatory strategy and compliance are essential for successful advancement to clinical trials.